CN103861107B - Pharmaceutical composition and uses thereof - Google Patents
Pharmaceutical composition and uses thereof Download PDFInfo
- Publication number
- CN103861107B CN103861107B CN201410075924.8A CN201410075924A CN103861107B CN 103861107 B CN103861107 B CN 103861107B CN 201410075924 A CN201410075924 A CN 201410075924A CN 103861107 B CN103861107 B CN 103861107B
- Authority
- CN
- China
- Prior art keywords
- tumor
- cell
- exosomes
- pharmaceutical composition
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a pharmaceutical composition and uses thereof. The pharmaceutical composition comprises a DNA methyltransferase inhibitor and a histone deacetylase inhibitor. The invention also discloses new uses of the pharmaceutical composition. The pharmaceutical composition is used to treat tumor cells together to obtain an exosomes tumor vaccine. The invention also discloses a method for preparing a tumor vaccine by using the pharmaceutical composition. The method comprises the following steps of using procaine and MS-275 to treat the tumor cells, and separating and purifying exosomes secreted by the tumor cells. The pharmaceutical composition disclosed by the invention improves the therapeutic effect of the exosomes tumor vaccine, and has an important clinical application value.
Description
Technical field
The present invention relates to a kind of medical composition and its use, be specifically related to a kind of pharmaceutical composition and preparing the novelty teabag of tumor vaccine, relate to more specifically a kind of comprise procaine and MS-275 pharmaceutical composition and purposes at preparation exosomes tumor vaccine.
Background technology
Procaine (procaine), chemical name 4 one amino benzoic Acid 2-(lignocaine) second vinegar, it is a kind of common local anaesthetics having used last 100 years clinically, this medicine can make cell membrane stability, reduce its permeability to ion, when neural impulse is reached, sodium, potassium ion can not pass in and out cell membrane and produce depolarization and action potential, thus produce local anesthetic action.In addition, procaine is also widely used in the middle of the treatment of clinical departments numerous disease, as being used for the treatment of pertussis the clinical of department of pediatrics, indomethacin, anaphylaxis purple paralysis, skin pruritus, neurodermatitis is used for the treatment of the clinical of department of dermatologry, be used for the treatment of cervix uteri difficult labour, cervical edema department of obstetrics and gynecology clinical, hasten parturition, be used for the treatment of pancreatitis the clinical of Gastroenterology dept., be used for the treatment of spitting of blood etc. the clinical of Pneumology Department.Although procaine also has anticancer effect, this drug effect needing higher concentration competence exertion desirable, makes him application in this regard be restricted.
MS-275 is that a kind of novel histone removes second phthalein enzyme inhibitor (Histone deacetylase inhibitor; HDACIs); HDACIs is by the activity of inhibition of histone deacetylase; change the Acetylation Level of histone; and then change chromatin Structure and function; thus remove the Transcription inhibition of special gene, the expression of controlling gene.MS-275 belongs to benzamides Antibiotic FR 901228, and he, using Benzoylamide group as functional group, is combined with zinc ion, plays a role.
In recent years, tumor is as a kind of disease of serious threat people life, its Therapeutic Method has become the problem that numerous researcher is devoted to study, along with immunology, cytobiology and molecular biological develop rapidly, after the large therapy of tumor operation, radiotherapy and chemotherapy three, the Biotherapeutics of tumor has become the fourth-largest therapy.Tumor biotherapy comprises immunization therapy, gene therapy, stem-cell therapy, inducing tumor cell differentiation and apoptosis, the treatment of Tumor suppression new vessels etc.Immunization methods tumor, receives much concern because its toxicity is lower, wherein the development of tumor vaccine especially people pay close attention to focus.
Tumor vaccine is mainly through activating patient's self immune system, utilize specific cellular immunity and the humoral immune reaction of tumor cell or tumor antigen material induction body, the anti-cancer ability of enhancing body, stops the growth of tumor, diffusion and recurrence, to reach the object removed or control tumor.Tumor vaccine is broadly divided into tumour-cell vaccine, tumor antigen and antigen-like molecule vaccine, nucleic acid vaccine, recombinant virus, disease vaccination and dendritic cell (dendritic cell, DC) vaccine.Tumour-cell vaccine extracts tumor cell from body tumor tissues, makes tumor cell lose oncogenicity, but still keep its immunogenicity, then carry out immunity to body after inactivation treatment; Tumor antigen and antigen-like molecule vaccine be utilize tumor antigen or class antigen determinant polypeptide, vaccination patient induce immune response prepared by anti-idiotype antibody; Nucleic acid vaccine refers to the plasmid containing certain antigenic protein gene sequence of coding as vaccine, in direct importing zooblast, by the re-recording system synthetic antigen albumen of host cell, induction host produces immunne response to this antigen protein, thus makes to be vaccinated animal and obtain corresponding immunoprotection; Recombinant virus, disease vaccination and dendritic cell vaccine refer to that people will carry the virus inoculation patient of gene of encoding tumor-antigens, cytokine, costimulatory molecules, bring out the immunne response of body for tumor by their expression in vivo; Dendritic cell vaccine refers to that the dendritic cell deriving from bone marrow be activated are at the high-caliber MHC I of cell surface expression, MHC II and ICAM and B7, and can activate T cells propagation, induce immune response.
Although a lot of to the correlational study of tumor vaccine both at home and abroad, but that up to the present makes a breakthrough is rare, the subject matter existed has: DNA being imported to specific cells, to carry out expressing this technology still immature, and use the safety issue of foreign DNA not yet to solve; Because tumor cell presents height heterogeneity, the multiple oncocytes belonging to same type tumor can express different antigen, the T cell activated by a kind of tumor antigen can only kill and wound the tumor cell of a part, and the oncocyte of not expressing this antigen then can not be killed and wounded; Although tumour-cell vaccine can comprise most tumor antigen, current research shows the limited use of its activated T cell, it can be used as the effect of vaccine unsatisfactory.
Exosomes is that a class originates from endocytosis system and is discharged in extracellular, the duplicature vesicle of diameter between 40-100nm.Exosomes can be secreted by the various kinds of cell comprising dendritic cell, tumor cell etc.Containing a large amount of and its source and the closely-related protein of function and lipid components, as the important carrier of intercellular trafficking information, participate in multiple pathophysiological process.The exosomes in tumor cell source contains the important immune molecule such as HLA-G, hot body gram albumen, and can show antineoplastic action by number of ways, and it is as a kind of novel tumor vaccine, comparatively DC vaccine has obvious advantage.
Exosomes is by intracellular multivesicular body (multivesicular bodies, MVB) with cell membrane fusion after, be discharged into the vesicle in extracellular environment, can be secreted by various kinds of cell, as dendritic cell, B cell, T cell, mastocyte, tumor cell etc.Exosomes antigen expressed can present correlation molecule MHCI and mhc class ii molecule, and with relevant tumor antigen information, has HLA-II antigen.Contained by the exosomes of different cell derived, albumen is different, and its function is not identical yet.Exosomes is except containing except cell nonspecific proteins composition, also contain tumor antigen as MAGE, molecular chaperones-heat shock protein (heat shock protein in NY-ESO-1 and antigen presentation process, HSP), can be used as new tumor antigen, activate in passing DC and produce tumour-specific CD8
+t cell immune response, and this immunological effect has cross-fire treatment effect.In addition, exosomes is cellular structures, can Quality Control when stable in physicochemical property, high temperature resistant, preparation, and comparatively cellularity tumor vaccine has more superiority.
But, but some related experiment are had to show in recent years, the exosomes in some tumors source can suppress or even destroy the immunocyte played a role in tumor, such as lower the expression of some NK receptors, have influence on the activation of some inherent immunity cells in tumour immunity, what also have significantly can suppress IL-2 thus the propagation of suppression Human Lymphocytes, thus in the immunization therapy of tumor, plays some negative effects.These exosomes originated by tumor may be exactly the key factor that tumor tissues escape body immune system is removed, and bring a lot of difficulty and challenge to the immunization therapy of tumor.Therefore, how to improve the immunostimulatory potency of tumor cell source exosomes, and the immunosuppression capability reducing it there is great practical significance in the immunization therapy of tumor.
The exosomes obtaining its secretion with procaine associating MS-275 process hepatoma cell line H22 cell of the invention, result show, the hepatoma carcinoma cell H22 without pharmaceutical composition process of the present invention secrete nanoscale vesicles---exosomes has significant inhibitory action to the proliferative function of lymphocyte; And can significantly improve this inhibitory action through the exosomes of pharmaceutical composition process hepatoma cell line H22 of the present invention emiocytosis.Pharmaceutical composition provided by the invention significantly improves exosomes and treats tumor effect, has important clinical value.
Summary of the invention
The object of the present invention is to provide a kind of medical composition and its use.
The object of the present invention is to provide a kind of pharmaceutical composition, described pharmaceutical composition comprises dnmt rna inhibitor and Antibiotic FR 901228.
As the ABC of this area, dnmt rna inhibitor refers to and can suppress dnmt rna activity, and the high methylation of blocking dna suppresses or kills the compound of tumor cell.The dnmt rna inhibitor researched and developed is more, and its chemical constitution mainly contains the large class of nucleoside and non-nucleoside two, is divided into by mechanism of action: mix DNA and with dnmt rna covalent bond; The noncovalently avtive spot of blocking dna transmethylase; The binding site of interference dnmt rna and DNA; Suppress the gene expression etc. of dnmt rna.
As the ABC of this area; Antibiotic FR 901228 refers to acetylation and the deacetylation of the lysine residue by regulating histone N-end, activates antioncogene, suppresses cancer gene; thus inhibition tumor cell growth, a compounds of inducing apoptosis of tumour cell.
Described drug treating tumor cell preferably adopts common dnmt rna inhibitor (DNAmethyltransferase inhibitor, DNMTi) to process.Common dnmt rna inhibitor includes but not limited to: azacitidine (5-azacytidine), decitabine (having another name called decitabine decitabine), Zebularine, 5-F-CdR, Hydralazine, SGI-1027, RG108, EGCC, procainamide (procainamide), procaine (procaine), MG-98, Psammaplin A, curcumin (curcumin) etc.
Described drug treating tumor cell preferably adopts common Antibiotic FR 901228 (histone deacetylase inhibitor, HDACi) to process.Common Antibiotic FR 901228 includes but not limited to: butanoic acid, valeric acid and benzenebutanoic acid and salt compounds thereof, trichostatin (trichostatin A, TSA), MS-275 (suberoylanilide hydroxamic), NVP-LAQ824, Pyroxamide, CBHA, Oxamflatin, Scriptaid, MM232, Trapoxin, Apicidin, FK228, WF3161, CHAP31, HC-toxin, LBH589, PDX-101, Tubacin, ACY-1215, MGCD0103, MS-275, Pomidepsin, Plitidepsin etc.
Further pharmaceutical composition preferred dnmt rna inhibitor procaine and Antibiotic FR 901228 MS-275.
Further preferred pharmaceutical compositions dnmt rna inhibitor procaine and Antibiotic FR 901228 MS-275 mol ratio 1: 1.
The invention provides a kind of preparation method of exosomes tumor vaccine, comprise drug treating tumor cell, the exosomes of isolation and purification tumor cell secretion.
The pharmaceutical composition process tumor cell containing procaine and MS-275 is preferably adopted to obtain exosomes tumor vaccine further.
Further, described tumor cell comprises ovarian cancer cell, melanoma cell, breast cancer cell, lung carcinoma cell, stomach cancer cell, colon cancer cell, hepatoma carcinoma cell, transitional cell bladder carcinoma cell line, leukaemia or glioma cell.
12-48 h before harvest supernatant after preferred dosing, more preferably 24 h before harvest supernatant.
The particle diameter of collected exosomes is made to be the microparticle of 40-100 nanometer substantially preferably by feasible method.Preferred, the tumor cell culture supernatant collected is removed cell with the centrifugal 10min of 300g, gets supernatant; Cell debris is removed with the centrifugal 30min of 1500g, collect supernatant, by 100kU MWCOCentriplus centrifugal ultrafiltration pipe ultrafiltration concentration, 6ml concentrated solution is obtained with the centrifugal 30min of 1500g, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, at 4 DEG C, namely contains exosomes with level angle with 100kg ultracentrifugation 60min gained precipitation.
The preparation method of preferred exosomes tumor vaccine, comprising: the DMEI culture fluid of tumor cell containing 100ml/L hyclone, at 37 DEG C of 50ml/L CO
2cultivate in incubator, cell is monolayer adherence growth, and every 3-4 days goes down to posterity 1 time, when Growth of Cells is to logarithmic (log) phase, by 3 × 10
6/ 100ml inoculates; With 1 × 10 after inoculation 24h
-6the pharmaceutical composition process of mol/L, after dosing, 24h collects culture supernatant respectively, and 4 DEG C of preservations.The tumor cell culture supernatant collected is removed cell with the centrifugal 10min of 300g, gets supernatant; Cell debris is removed with the centrifugal 30min of 1500g, collect supernatant, by 100kU MWCO Centriplus centrifugal ultrafiltration pipe ultrafiltration concentration, 6ml concentrated solution is obtained with the centrifugal 30min of 1500g, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, at 4 DEG C, namely contains exosomes with level angle with 100kg ultracentrifugation 60min gained precipitation.
Tumor vaccine provided by the invention can be any dosage form and medication specification of being suitable for clinical practice, such as, can be injection.The preparation method vaccine preparation method also comprised conveniently of described tumor vaccine makes required dosage form, such as, make injection, can be to make injection by adding normal saline, also can make injectable powder etc.
Further, exosomes tumor vaccine adds corresponding adjuvant.
Further, described adjuvant is aluminium adjuvant.
Tumor vaccine provided by the invention by subcutaneous or administered intramuscular, can carry out immunity to individuality, occurs or killing tumor cell with Tumor suppression.
The invention provides described tumor vaccine and prepare the application in antitumor drug.
Further described antitumor can be anti-leukemia, osteocarcinoma, lymphatic cancer, intestinal cancer, hepatocarcinoma, gastric cancer, pelvic cancer, pulmonary carcinoma, the brain cancer, neural cancer, breast carcinoma, esophageal carcinoma, renal carcinoma one or more.
Antitumor described is further anti-hepatocarcinoma.
Scheme provided by the invention has the following advantages:
(1) the tumor vaccine spectrotype prepared of pharmaceutical composition provided by the invention extensively, comprehensively, can realize effectively killing and wounding nearly all tumor cell.
(2) tumor vaccine prepared of pharmaceutical composition provided by the invention, little to the toxic and side effects of body, use safety.
(3) tumor vaccine prepared of pharmaceutical composition provided by the invention, can also can as preventative vaccine as therapeutic vaccine, use in the different oncotherapy stages, by activating body immune system, the generation of prophylaxis of tumours or existing tumor cell is is effectively killed and wounded.
Accompanying drawing explanation
Fig. 1 exosomes corpusculum Electronic Speculum figure
Detailed description of the invention
Embodiments of the invention are described below in detail only for explaining the present invention; and limitation of the present invention can not be interpreted as; should be understood that; for those skilled in the art; under the premise without departing from the principles of the invention; can also make some improvement, these improvement also should be considered as protection scope of the present invention.
Embodiment 1 cell culture
Experiment material: H22 cell strain, 10% hyclone, mycillin mixed liquor (Beijing company of Tag U.S.).
Experimental technique: H22 cell strain is incubated in the culture fluid containing 10% hyclone, penicillin 100IU/mL, streptomycin 10O × μ g/mL, at 37 DEG C of 5%CO
2cultivate in incubator, when Growth of Cells is to logarithmic (log) phase, by 3 × 10
6/ 100ml inoculates.
Embodiment 2 drug treating
Experiment material: procaine, MS-275 (all purchased from sigma company).
Experiment grouping: cell culture fluid volume often organizes strict conformance, blank group, exosomes matched group (not dosing group), exosomes experimental group 1 (dosing procaine), exosomes experimental group 2 (dosing MS-275), exosomes experimental group 3 (procaine and MS-275 associating dosing).
Experimental technique: matched group, does not add medicine after inoculation, collects supernatant 150ml in contrast after 24h; Dosing group 1, by concentration 1 × 10 after inoculation 24h
-6the procaine process of mol/L, after dosing, 24h collects each 150ml of culture supernatant respectively; Dosing group 2, by concentration 1 × 10 after inoculation 24h
-6the MS-275 process of mol/L, after dosing, 24h collects each 150ml of culture supernatant respectively; Dosing group 3, with 1 × 10 after inoculation 24h
-6the procaine of mol/L and 1 × 10
-6the MS-275 process of mol/L, after dosing, 24h collects each 150ml of culture supernatant respectively, and 4 DEG C of preservations.
The isolation and purification of embodiment 3exosomes
Experimental apparatus: HMAC-CP70G low temperature Ultracentrifuge, 100KU MW CO Millipore Amicon high-recovery high flow rate cross-flow ultrafiltration centrifuge tube (Millipore company).
Experimental technique: the experimental group collected and cellular control unit culture supernatant are removed cell with the centrifugal 10min of 300g, gets supernatant; Cell debris is removed with the centrifugal 30min of 1500g, collect supernatant, by 100kUMWCO Centriplus centrifugal ultrafiltration pipe ultrafiltration concentration, 6ml concentrated solution is obtained with the centrifugal 30min of 1500g, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, at 4 DEG C, namely contains exosomes with level angle with 100kg ultracentrifugation 60min gained precipitation.
The Electronic Speculum qualification of embodiment 4exosomes
Drip 20-30 μ l exosomes suspension on load sample copper mesh, room temperature leaves standstill lmin filter paper and blots liquid from side, drip 20ml/L Salkowski's solution (pH6.8) about 30 μ l on copper mesh, room temperature negative staining lmin filter paper blots negative staining liquid, observes and take a picture under room temperature under drying about lOmin transmission electron microscope.Result as shown in Figure 1.The exosomes corpusculum diameter of H22 emiocytosis under Electronic Speculum is the film microcapsule structure of 30-80nm, rounded or oval, and intracavity is low electron density composition.(increasing description and the discussion of result)
Embodiment 5H3-TdR incorporation methods detects PBMC cell proliferative condition
Experiment material: H
3-TdR (Shanghai nuclear research institute), mycillin mixed liquor (Beijing company of Tag U.S.), hyclone
Experimental apparatus: β-liquid scintillation counter measurement (FJ-2107G type)
Experiment grouping: blank group (only adding phytohemagglutinin and PBMC cell), exosomes matched group (not dosing group), exosomes experimental group 1 (dosing procaine), exosomes experimental group 2 (dosing MS-275), exosomes experimental group 3 (procaine and MS-275 associating dosing), supernatant matched group (not dosing group) after exosomes extracts, supernatant experimental group 1 (dosing procaine) after exosomes extracts, supernatant experimental group 2 (dosing MS-275) after exosomes extracts, supernatant experimental group 3 (procaine and MS-275 associating dosing) after exosomes extracts, every component is three wells.
Experimental technique: the PBMC cell of separator well adds the fresh RPMI1640 culture medium of 5ml containing 10% hyclone, after cell counting, dilution is 5000/50 microlitres, according to previous ready-made labelling, add in 96 orifice plates with 50 microlitres/hole, simultaneously add the mixed liquor of penicillin 100IU/mL, streptomycin 10O × μ g/mL with the ratio of 1: 1000, then add 50 μ l samples, finally add 100 μ lIPHA.Put into 37 DEG C of 50%CO
2incubator spends the night, second day can lO × inverted microscope under observe PBMC cell be bulk propagation, by H
3-TdR adds in culture plate, every hole 3.7 × 10
4individual Bq goes culture medium, washes 3 times with 1 × PBS, the NaOH broken cell film of lmol/L, add scintillation solution and appropriate anti-quencher after continuing to cultivate 6h, with β-liquid scintillation counter measurement, and record cpm value (minute counting).Result is as shown in table 1.
The supernatant of table 1 after the exosomes before and after combination medicine process and extraction is on the impact of PBMC cell proliferation
| Group | Group number | Cpm value (X ± S) |
| Blank | 3 | 24016±2001.25 |
| Exosomes matched group | 3 | 3635±19.98 |
| Exosomes experimental group 1 | 3 | 19012±775.62 |
| Exosomes experimental group 2 | 3 | 19125±763.51 |
| Exosomes experimental group 3 | 3 | 23768±701.21 |
| Supernatant matched group after exosomes extracts | 3 | 2987±501.99 |
| Supernatant experimental group 1 after exosomes extracts | 3 | 21532±6482.36 |
| Supernatant experimental group 2 after exosomes extracts | 3 | 20461±6621.89 |
| Supernatant experimental group 3 after exosomes extracts | 3 | 23998±6006.21 |
Result shows: compared with blank group, after exosomes and the PBMC co-culture of cells of drug treating, have appreciable impact to lymphopoiesis, obviously reduces (P < 0.05), through drug treating, obviously can improve the suppression of exosomes to the proliferative function of lymphocyte, the exosomes (exosomes experimental group 3) wherein obtained after pharmaceutical composition process is minimum to the suppression of the proliferative function of lymphocyte, exosomes (exosomes experimental group 1 and exosomes experimental group 2) is obtained to lymphopoietic suppression after being significantly less than drug alone process, there is significant difference (P < 0.05) in PBMC propagation value and exosomes matched group comparative statistics, compare with blank group without significant difference (P > 0.05).At experimental group, after the supernatant of drug treating after exosomes extracts and PBMC co-culture of cells, on cell proliferation is almost without impact, compare without remarkable significant difference (P > 0.05) with blank group, supernatant without drug treating then has a significant impact the proliferative function of lymphocyte, and statistically all there were significant differences compared with blank group or supernatant experimental group (P < 0.05).
Embodiment 6 tumor inhibition
Experiment material: healthy kunming mouse, murine hepatocarcinoma cell (H22), RPMI1640 culture medium (purchased from GIBCO), hyclone
Experimental technique:
(1) set up mice with tumor model: H22 mouse ascites is got by sterile working, Trypan Blue, oncocyte counting under light microscopic, oncocyte 9000 of living, adjustment cell concentration is 1 × 10
7individual/ml, in every mice right axil subcutaneous vaccination 0.2ml, makes solid type mice with tumor model.
(2) tumor vaccine is prepared: carry out cell culture according to described embodiment 1; Cultured cells is divided into 4 groups, first group of not dosing, second group of dosing procaine, the 3rd group of dosing MS-275, the 4th group of procaine and MS-275 associating dosing, concrete agent-feeding treatment is with reference to embodiment 2; The each group of cell culture supernatant collected is prepared exosomes tumor vaccine with reference to embodiment 3.
(3) grouping and treatment: mice 30 is divided into 5 groups at random, often organizes each 6.Blank group: tumor-bearing mice intraperitoneal injection of saline; Exosomes matched group: tumor cell inoculation same day, in tumor vaccine (10 μ g/ only) prepared by mice lower limb root subcutaneous injection first group; Exosomes experimental group 1: tumor cell inoculation same day, in tumor vaccine (10 μ g/ only) prepared by mice lower limb root subcutaneous injection second group; Exosomes experimental group 2: tumor cell inoculation same day, in mice lower limb root subcutaneous injection the 3rd group of tumor vaccine prepared (10 μ g/ only); Exosomes experimental group 3: tumor cell inoculation same day, in mice lower limb root subcutaneous injection the 4th group of tumor vaccine prepared (10 μ g/ only).Repeated 1 time at interval of 1 day, totally 3 times.All mices are put to death for the 15th day after inoculated tumour, get tumor body, weigh, survey gross tumor volume, calculate tumor-like hyperplasia, gross tumor volume suppression ratio.
(4) take tumor weight and calculate tumor control rate
After sacrifice, take out tumor tumor body respectively, peel off totally, wipe clean blood stains with filter paper, electronic balance takes tumor weight, calculates tumour inhibiting rate:
Tumour inhibiting rate (%)=(matched group tumor size-treatment group tumors size)/matched group tumor size × 100%.
Table 2 tumor vaccine is to the inhibitory action of transplanted human hepatocellular carcinoma
| Experiment grouping | Tumor average quality |
| Blank group | 2.78±0.29 |
| Exosomes matched group | 1.76±0.16 |
| Exosomes experimental group 1 | 1.32±0.14 |
| Exosomes experimental group 2 | 1.29±0.17 |
| Exosomes experimental group 3 | 0.97±0.13 |
After adopting exosomes tumor vaccine therapy, Growth of Transplanted Hepatocarcinoma in Mice is suppressed, exosomes experimental group 1, exosomes experimental group 2, exosomes experimental group 3 tumor quality is respectively (1.32 ± 0.14) g, (1.29 ± 0.17) g, (0.99 ± 0.13) g, with blank group (2.78 ± 0.29) g, exosomes matched group, (1.76 ± 0.16) g is than significant difference (P < 0.05), tumor vaccine inhibitory action prepared by procaine and MS-275 associating dosing is the strongest, tumor quality is (0.99 ± 0.13) g, inhibitory rate 65.11%.
The invention provides a kind of pharmaceutical composition, uses this pharmaceutical composition process tumor cell, and the exosomes of the tumor cell secretion after process significantly can improve the inhibitory action of former exosomes to the proliferative function of lymphocyte.Zoopery shows, adopts exosomes tumor vaccine therapy Be very effective prepared by pharmaceutical composition process of the present invention, has important clinical value.
Claims (8)
1. a pharmaceutical composition, described pharmaceutical composition comprises dnmt rna inhibitor and Antibiotic FR 901228, it is characterized in that, described dnmt rna inhibitor is procaine; Described Antibiotic FR 901228 is MS-275; Described dnmt rna inhibitor and Antibiotic FR 901228 ratio are 1:1.
2. pharmaceutical composition according to claim 1 is preparing the purposes in tumor vaccine.
3. prepare a method for tumor vaccine, it is characterized in that, described method comprises: use the pharmaceutical composition process tumor cell described in claim 1; The exosomes of isolation and purification tumor cell secretion.
4. the method preparing tumor vaccine according to claim 3, comprising: the DMEI culture fluid of tumor cell containing 100ml/L hyclone, at 37 DEG C of 5Oml/L CO
2cultivate in incubator, cell is monolayer adherence growth, and every 3-4 days goes down to posterity 1 time, inoculates to during logarithmic (log) phase until Growth of Cells; With pharmaceutical composition process cell according to claim 1 after inoculation 24h, after dosing, 24h collects culture supernatant respectively, and 4 DEG C of preservations; By the tumor cell culture supernatant centrifugal segregation cell collected, get supernatant; Centrifugal segregation cell debris again, collect supernatant, by 100kU MWCO Centriplus centrifugal ultrafiltration pipe ultrafiltration concentration, centrifugally obtain concentrated solution, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, use level angle with 100kg ultracentrifugation at 4 DEG C, gained precipitation is namely containing exosomes.
5. the tumor vaccine that the method preparing tumor vaccine according to claim 3-4 any one is obtained.
6. tumor vaccine as claimed in claim 5, it is characterized in that, described tumor vaccine comprises adjuvant.
7. the application in antitumor drug prepared by the tumor vaccine as described in claim 5-6 any one.
8. apply as claimed in claim 7, it is characterized in that, described antitumor drug is medicines resistant to liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410075924.8A CN103861107B (en) | 2014-03-04 | 2014-03-04 | Pharmaceutical composition and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410075924.8A CN103861107B (en) | 2014-03-04 | 2014-03-04 | Pharmaceutical composition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103861107A CN103861107A (en) | 2014-06-18 |
| CN103861107B true CN103861107B (en) | 2015-01-14 |
Family
ID=50900491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410075924.8A Expired - Fee Related CN103861107B (en) | 2014-03-04 | 2014-03-04 | Pharmaceutical composition and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103861107B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110124020B (en) | 2019-05-05 | 2023-03-14 | 海南医学院 | Tumor cell vaccine prepared based on extracellular trapping net principle and preparation method thereof |
| CN111000867B (en) * | 2020-01-07 | 2022-04-29 | 河北医科大学 | Application of tumor cell supernatant after chemotherapy drug action |
| CN114908049A (en) * | 2021-02-10 | 2022-08-16 | 江苏集萃医学免疫技术研究所有限公司 | Use of HDAC6 inhibitors to selectively induce T cell expansion |
| CN115819602A (en) * | 2022-12-09 | 2023-03-21 | 北京高科创航科技有限公司 | Pharmaceutical composition with proliferation and apoptosis regulating effect on cells and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088969A (en) * | 2008-06-09 | 2011-06-08 | 西克拉塞尔有限公司 | Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
-
2014
- 2014-03-04 CN CN201410075924.8A patent/CN103861107B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088969A (en) * | 2008-06-09 | 2011-06-08 | 西克拉塞尔有限公司 | Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
Non-Patent Citations (2)
| Title |
|---|
| 董伟伟 等.exosomes:肿瘤免疫治疗新进展.《医学研究杂志》.2012,第41卷(第4期),第10页. * |
| 董伟伟 等.外体(exosomes)在肿瘤免疫治疗中的应用.《生物技术通讯》.2009,第20卷(第2期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103861107A (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berger et al. | Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma | |
| CN103446580B (en) | A kind of tumor vaccine and preparation method thereof | |
| KR20180042284A (en) | Smallpox vaccine for use in cancer treatment | |
| CN103861107B (en) | Pharmaceutical composition and uses thereof | |
| CN103816535B (en) | Tumour vaccine and preparation method thereof | |
| CN103648524A (en) | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells | |
| CN101361732B (en) | Medicinal preparation containing garcinia acid and use thereof | |
| CN106867963A (en) | Ray modification umbilical cord adult stem cell 3D microballoon work preparation and its preparation and application | |
| JP7017011B2 (en) | Mycobacterium paragordone anti-cancer immunotherapeutic use | |
| CN109939127A (en) | The application of NK cell and pharmaceutical composition and its application including the NK cell | |
| CN105169379A (en) | Tumor vaccine for treating stomach cancer and preparing method of tumor vaccine | |
| CN113117088A (en) | Use of calcium-activated chloride channel inhibitors in tumor immunotherapy | |
| CN105288603A (en) | Tumor vaccine for treating liver cancer and preparing method thereof | |
| JP2019031470A (en) | Antitumor composition containing nk cell conditioned medium and method for producing the same | |
| CN103463098B (en) | Application of hederagenin for preparing antineoplastic drugs | |
| RU2379055C1 (en) | Method of treating oncological diseases | |
| AU2003277641B2 (en) | Remedy for cancer | |
| CN102440994A (en) | Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments | |
| WO2021024897A1 (en) | Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment | |
| CN102309493B (en) | Anti-cancer medicinal composition | |
| Mallmann | Tumor vaccination | |
| Schultz et al. | Immunotherapy with allogeneic immune peritoneal cells activated by BCG or pyran copolymer | |
| Sun et al. | IMMU-28. TREM2 INHIBITION REPROGRAMS MYELOID CELLS TO STIMULATE ANTI-TUMOR IMMUNITY THROUGH BOTH DIRECT AND INDIRECT MECHANISMS | |
| Zou et al. | Advancing nanotechnology for neoantigen-based cancer theranostics | |
| CN104523699B (en) | Hederagenin is preparing the application in ovarian cancer resistance HO-8910PM tumour medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NO.1 HOSPITAL ATTACHED TO PLA GEN. HOSPITAL Free format text: FORMER OWNER: XIAO WENHUA Effective date: 20140904 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140904 Address after: 100048 Beijing city Haidian District Fuchengmen Road No. 51 Applicant after: The First Affiliated Hospital of General Hospital of PLA Address before: 100048 Beijing city Haidian District Fuchengmen Road No. 51 Applicant before: Xiao Wenhua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150114 Termination date: 20190304 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |